Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06417190 | Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology | recruiting | Phase 2 | 20 | Leslie BallasOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749924 | Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC | not yet recruiting | N/A | 670 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 75 | Matthew GalskyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy(GAIN-BCG) | recruiting | Phase 3 | 330 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | terminated | Phase 1 / Phase 2 | 272 | Hoffmann-La RocheINDUSTRY | 7 | Aug 3, 2026 | clinicaltrials |
| NCT04934540 | The Global En Bloc Resection of Bladder Tumour Registry | recruiting | — | 2,000 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07724886 | Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC | not yet recruiting | N/A | 732 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03047213 | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03237780 | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03854474 | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07225127 | Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2(CISTO2) | recruiting | — | 408 | University of WashingtonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07646847 | A Study of a Side Effects and Resource Navigation Program for People With Cancer | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06963346 | Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | recruiting | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07735858 | Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer | active not recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05756569 | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | recruiting | Phase 2 | 25 | Emory UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07728474 | LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder(LCS103) | recruiting | N/A | 60 | LifeBiotic Medical Research Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07727343 | AI-Guided TURBT for Bladder Cancer(AITURBT) | not yet recruiting | N/A | 170 | Fudan UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | active not recruiting | Phase 2 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725796 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | not yet recruiting | Phase 1 | 30 | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06405425 | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721935 | Development of an AI-Agent for Urological Disease Diagnosis and Treatment | recruiting | — | 2,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)(KEYNOTE-866) | completed | Phase 3 | 907 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT04081246 | Transurethral Modified En Bloc Resection For Large Bladder Tumours. | completed | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | recruiting | Phase 2 | 372 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | active not recruiting | Phase 3 | 412 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 24 | Jul 22, 2026 | clinicaltrials |
| NCT07095751 | Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer | not yet recruiting | N/A | 60 | Chinese University of Hong KongOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720921 | Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )(LUXUS0701) | not yet recruiting | Phase 2 | 20 | Peking University First HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT07207824 | DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC(HERO) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07307456 | Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration(MARINE-01) | recruiting | Phase 2 | 31 | Changhai HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07717242 | Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer(SYSTEM) | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05531123 | Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05833867 | Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 20 | Shilpa Gupta, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC | recruiting | Phase 3 | 236 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03504163 | Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | active not recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT00848289 | Genetic Susceptibility to Bladder Cancer | active not recruiting | — | 6,086 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2026source: clinicaltrials